TheProfitWatch

MRNA - Moderna, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
22.62 0.86 (3.78%) -0.02 (-0.09%) -0.05 (-0.23%) -0.04 (-0.19%) -0.18 (-0.8%) 1.09 (4.85%) 0.1 (0.44%) 0.06 (0.27%)

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-2.13
Diluted EPS:
-2.13
Basic P/E:
-11.0211
Diluted P/E:
-11.0211
RSI(14) 1m:
57.14
VWAP:
23.48
RVol:

Events

Period Kind Movement Occurred At

Related News